乳腺癌是一种激素依赖性并且高度异质性的恶性肿瘤。内分泌治疗是重要治疗手段之一,尤其对于Luminal A型和Luminal B型乳腺癌患者。其中Luminal B型乳腺癌又分为Luminal B-HER2-型和Luminal B-HER2+型,后者新辅助/辅助治疗上可以应用化疗、内分泌治疗以及抗HER2靶向治疗,但是部分人群对化疗不敏感,内分泌以及靶向HER2治疗耐药,已成为临床上的瓶颈。本文总结了近年国内外针对此类型乳腺癌的探索耐药机制的新进展以及治疗方案。 Breast cancer is a hormone-dependent and highly heterogeneous malignancy. Endocrine therapy is one of the important treatments, especially for Luminal A and Luminal B type breast cancer patients. Among them, Luminal type B breast cancer is divided into Luminal B-HER2-type and Luminal B-HER2 type. The latter can be applied with neoadjuvant / adjuvant chemotherapy, endocrine therapy and anti-HER2 targeted therapy, but some people are not sensitive to chemotherapy , Endocrine and target HER2 treatment resistance, has become a clinical bottleneck. This article summarizes recent advances in researching drug resistance mechanisms for this type of breast cancer at home and abroad, as well as treatment options.